Under copycat attack, Amgen punches back with its own biosimilars

Amgen spent years bracing for biosimilar and generic competition to its top-selling meds, but now its own biosimilars are kicking in sales to help fill those patent-cliff gaps.

Amgen’s biosimilars pulled in $173 million in the third quarter—up from $19 million during the same period last year—which at least softened the blow from copycats to Sensipar, Neulasta and Neupogen. Overall, the company's revenues slipped 3% to $5.7 billion.